Safety, Pharmacokinetics, and Pharmacodynamics of the New Aldose Reductase Inhibitor Govorestat (AT‐007) After a Single and Multiple Doses in Participants in a Phase 1/2 Study

Documenti analoghi

• Treatment of Single Patient With PMM2 ‐Congenital Disorder of Glycosylation With Govorestat ( AT ‐007), an Aldose Reductase Inhibitor
  di: Elizabeth R. Jalazo, et al.
  Pubblicazione: (2025)
• Results of the ACTION‐Galactosemia Kids Study to Evaluate the Effects of Govorestat in Pediatric Patients with Classic Galactosemia
  di: Evan Bailey, et al.
  Pubblicazione: (2024)
• Safety, Pharmacokinetics, and Pharmacodynamics of Etrasimod: Single and Multiple Ascending Dose Studies in Healthy Adults
  di: Caroline A. Lee, et al.
  Pubblicazione: (2024)
• A Randomized, Parallel, Open‐Label, Single‐Dose and Multiple‐Dose Clinical Trial to Investigate the Pharmacokinetic, Pharmacodynamic, and Safety Profiles of Obicetrapib in Healthy Participants in China
  di: Jing Zhang, et al.
  Pubblicazione: (2024)
• Safety, Tolerability, and Pharmacokinetics of Single‐ and Multiple‐Ascending Doses of Sunobinop in Healthy Participants
  di: Alessandra Cipriano, et al.
  Pubblicazione: (2024)